Gene Expression Profile-Based Risk Modeling to Select Patients With Melanoma Who Can Avoid Sentinel Lymph Node Biopsy: Are We There Yet?-Reference-Cited by-同舟云学术

Gene Expression Profile-Based Risk Modeling to Select Patients With Melanoma Who Can Avoid Sentinel Lymph Node Biopsy: Are We There Yet?

Published:2020-11 Issue:4 Volume: Page:988-989
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precision Oncology

Author:

Bartlett Edmund K.¹,Marchetti Michael A.¹,Coit Daniel G.¹

Affiliation:

1. Edmund K. Bartlett, MD, Gastric and Mixed Tumor Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Michael A. Marchetti, MD, Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; and Daniel G. Coit, MD, Gastric and Mixed Tumor Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.20.00146

Reference10 articles.

1. Model Combining Tumor Molecular and Clinicopathologic Risk Factors Predicts Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma

2. Clinicopathologic Predictors of Sentinel Lymph Node Metastasis in Thin Melanoma

3. Identification of Patients with Intermediate Thickness Melanoma at Low Risk for Sentinel Lymph Node Positivity

4. Association Between Patient Age and Lymph Node Positivity in Thin Melanoma

5. Three myths about risk thresholds for prediction models

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CP-GEP (Merlin) gene expression profiling: can my melanoma patient forgo sentinel lymph node biopsy?;Italian Journal of Dermatology and Venereology;2023-08

2. Breslow thickness 2.0: Why gene expression profiling is a step toward better patient selection for sentinel lymph node biopsies;Modern Pathology;2022-11

3. Reply to E. K. Bartlett et al and A. H. R. Varey et al;JCO Precision Oncology;2020-11